Ensysce Biosciences's EBIT per Share for the
three
months ended in Dec. 2024 was $-2.62.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-9.83.
During the past 3 years, the average EBIT per Share Growth Rate was 85.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Ensysce Biosciences's EBIT per Share or its related term are showing as below:
ENSC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 32.5 Med: 59.1 Max: 85.7
Current: 85.7
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Ensysce Biosciences was 85.70% per year. The lowest was 32.50% per year. And the median was 59.10% per year.
ENSC's 3-Year EBIT Growth Rate is ranked better than 99.43% of 1224
companies
in the Biotechnology industry
Industry Median: 4.2
vs ENSC: 85.70
Ensysce Biosciences EBIT per Share Historical Data
The historical data trend for Ensysce Biosciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.83
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ensysce Biosciences (NAS:ENSC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Ensysce Biosciences EBIT per Share Related Terms
Thank you for viewing the detailed overview of Ensysce Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENSC has been successfully added to your 